

Press release

**Genomtec plans to issue shares. The proceeds will be used to support the M&A process and commercialize projects.**

**The company has concluded an investment agreement with a key shareholder.**

**Wrocław, March 17, 2026 – Genomtec S.A., a molecular diagnostics company (WSE ticker: GMT), has called an Extraordinary General Meeting (EGM) on April 13, 2026, at which the Shareholders will vote on an increase in the Company's share capital through the issue of up to 2 million new series R shares and up to 204,000 series S shares, excluding pre-emptive rights.**

Genomtec intends to use the funds raised from the new share issue primarily to support the M&A process and further implement key development projects. The funding will primarily cover testing the diagnostic parameters of the 3-plex variant of the Genomtec ID platform in the context of potential M&A transactions, as well as continuing projects that have already received grant funding. In this regard, the company plans to design and manufacture prototypes of reaction cards and the OncoSNAAT® analyzer for research purposes, as well as support a project utilizing AI solutions to develop primer sets for molecular diagnostics.

**As part of the planned transaction, on March 17th of this year, the Company entered into an investment agreement with a significant shareholder, 5HT Family Foundation, under which the Shareholder agreed to conduct a public offering of up to 2 million existing shares, borrowed from Miron Tokarski, President of the Management Board of Genomtec, and Małgorzata Małodobra-Mazur, and to use all the proceeds to acquire newly issued Series R shares. Genomtec will thus obtain funds from the sale of Series R shares, which will be used to support the commercialization of projects as part of the M&A process conducted by Genomtec. Additionally, Genomtec obtained a PLN 1 million loan from shareholder 5HT Family Foundation with the right to convert the loan into shares.**

*"Over the past year, we have developed several key changes to the successful commercialization of our projects. The advanced Genomtec ID and OncoSNAAT® projects These were spun off into separate special purpose vehicles: GMT ID SA and GMT GENOMICS SA. This reorganization allows us to offer each project separately, significantly increasing transaction flexibility and enabling us to better adapt to buyers' expectations during the M&A process. Furthermore, we have revised our model of cooperation with M&A advisors, optimizing costs and taking control of the process, allowing us to operate more proactively and effectively in the market. We conduct M&A activities in both Western markets and Asia. Potential partners have expressed a need to verify our technology, confirming the market demand for technologies developed by Genomtec. Offering investors shares in existing companies streamlines the entire process. This structure allows investors to acquire listed shares, thus*

significantly simplifying capital entry into Genomtec. At the same time, the involvement of a significant shareholder in this mechanism does not limit their stake in the company. Securing capital remains crucial for achieving the success of the M&A process, which is why we count on the support of shareholders for the resolution on the issue of new shares during the Extraordinary General Meeting", says Miron Tokarski, President of the Management Board and co-founder of Genomtec SA.

The company's flagship project is the Genomtec ID<sup>®</sup> mobile diagnostic system, which consists of an analyzer and a reaction card with integrated genetic tests. The Genomtec ID<sup>®</sup> platform is based on the proprietary SNAAT<sup>®</sup> solution and stands out from the competition for its mobility, speed, and ability to simultaneously diagnose multiple pathogens at the point of care. The OncoSNAAT<sup>®</sup> project, in turn, is a technology for detecting genetic changes occurring in cancer, which is crucial in personalized medicine, for example, when selecting targeted oncology treatments.

#### *Legal disclaimer*

*This publication is for informational purposes only and does not serve to promote, directly or indirectly, the Company's share offering by any shareholder. It does not constitute promotional material or advertising prepared or published by the Company for the purpose of promoting or subscribing to the Company's shares, or encouraging, directly or indirectly, the purchase of the Company's shares. This publication does not constitute a prospectus or any other memorandum, information document, or offering document. No prospectus will be issued in connection with the matters covered by this publication, and no prospectus is required. This publication does not contain or constitute an offer to sell or subscribe for securities, nor a solicitation of an offer to purchase securities, nor a solicitation/recommendation to purchase securities. It does not constitute an investment recommendation within the meaning of applicable law and, under no circumstances, constitutes the basis for making a decision to purchase the Company's securities. This publication and the information contained herein are restricted and not for publication, announcement, distribution or transmission, directly or indirectly, in whole or in part, in or into the United States of America, Australia, Canada, South Africa, Japan or any other country where such publication, announcement, distribution or transmission would be unlawful.*

---

#### **About Genomtec:**

Genomtec is a MedTech company specializing in developing advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for quick and precise molecular analysis outside the laboratory environment without the need for qualified laboratory personnel. The solution utilizes microfluidic technology and proprietary, patented isothermal technology. SNAAT<sup>®</sup> Genomtec's technology is protected by 20 patents in Europe, the US, and Japan, among others, and the company has over 30 patent applications pending.

The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections

The company is headquartered in Wrocław. Genomtec also has a presence in the UK, where an office and part of its international research and engineering team are located.

More information is available on the company's website: [www.genomtec.com](http://www.genomtec.com)

#### **Media contact:**

Michał Wierzchowski

Tel.: +48 531 613 067

[michal.wierzchowski@ccgroup.pl](mailto:michal.wierzchowski@ccgroup.pl)



**Contact for investors:**

Agata Dzieciółowska

Tel.:+48 606 205 119

[agata.dzieciolowska@ccgroup.pl](mailto:agata.dzieciolowska@ccgroup.pl)